{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:07:01Z","timestamp":1779962821793,"version":"3.53.1"},"reference-count":87,"publisher":"Charles University in Prague, Karolinum Press","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":447,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":447,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["UHHK, 00179906"],"award-info":[{"award-number":["UHHK, 00179906"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["actamedica.lfhk.cuni.cz"],"crossmark-restriction":true},"short-container-title":["Acta Med. (Hradec Kralove, Czech Repub.)"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Over the past decade, chronic lymphocytic leukemia (CLL) management has undergone a fundamental transformation driven by the introduction of oral targeted inhibitors. Continuous Bruton tyrosine kinase (BTK) inhibition and time-limited BCL-2\u2013based therapy has replaced chemoimmunotherapy as the standard of care, improving survival and quality of life. Ibrutinib and its next-generation analogues, acalabrutinib and zanubrutinib, provide durable disease control with improved safety. At the same time, venetoclax combined with anti-CD20 antibodies enables deep and measurable residual disease (MRD)-negative remissions within fixed-duration regimens. Recent trials have demonstrated the feasibility of MRD-guided treatment cessation and the potential benefit of combining BTK and BCL-2 inhibition to achieve durable, chemotherapy-free responses. Ongoing research focuses on optimizing treatment sequencing, overcoming acquired resistance through non-covalent BTK inhibitors, and integrating immunotherapeutic modalities such as bispecific antibodies and CAR-T cells. The current paradigm emphasizes individualized, biomarker- and comorbidity-driven therapy based primarily on TP53 and IGHV status, with treatment selection tailored to patient fitness, tolerance, and long-term safety. This review summarizes contemporary evidence, clinical practice recommendations, and future directions in the targeted management of CLL.<\/jats:p>","DOI":"10.14712\/18059694.2026.1","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:41:23Z","timestamp":1774356083000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.14712\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Are We Moving Toward Curative Approaches in Chronic Lymphocytic Leukemia?"],"prefix":"10.14712","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-5334","authenticated-orcid":false,"given":"Martin","family":"\u0160imkovi\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Vejra\u017ekov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"\u00c9csiov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Vod\u00e1rek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5727","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"18059694.2026.1_1","doi-asserted-by":"crossref","unstructured":"Walewska R, Eyre TA, Bloor A, et al. 2025 British Society for Haematology Guideline for the Treatment of Chronic Lymphocytic Leukaemia. Br J Haematol. 2025 Oct 9.","DOI":"10.1111\/bjh.70100"},{"key":"18059694.2026.1_2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol."},{"key":"18059694.2026.1_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"Landau","year":"2015","journal-title":"Nature."},{"key":"18059694.2026.1_4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"Damle","year":"1999","journal-title":"Blood."},{"key":"18059694.2026.1_5","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA."},{"key":"18059694.2026.1_6","doi-asserted-by":"crossref","unstructured":"Burger JA, Barr PM, Robak T, et al. Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-up of First-Line Ibrutinib Treatment for CLL\/SLL. Blood. 2025 Jul 30.","DOI":"10.1182\/blood.2024028205"},{"key":"18059694.2026.1_7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"key":"18059694.2026.1_8","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41375-024-02334-3","volume":"38","author":"Gambril","year":"2024","journal-title":"Leukemia."},{"key":"18059694.2026.1_9","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021 Jul 26.","DOI":"10.1200\/JCO.21.01210"},{"key":"18059694.2026.1_10","doi-asserted-by":"crossref","unstructured":"Brown JR, Byrd JC, Ghia P, et al. Cardiovascular Adverse Events in Patients with Chronic Lymphocytic Leukemia Receiving Acalabrutinib Monotherapy: Pooled Analysis of 762 Patients. Haematologica. 2020.","DOI":"10.3324\/haematol.2021.280310"},{"key":"18059694.2026.1_11","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 6-Year Results of the Randomized Phase 3 CLL14 Study. Blood. 2024 Jul 14.","DOI":"10.1097\/01.HS9.0000967492.06443.0a"},{"key":"18059694.2026.1_12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol."},{"key":"18059694.2026.1_13","doi-asserted-by":"crossref","unstructured":"Kater AP, Harrup RA, Kipps TJ, et al. The MURANO Study: Final Analysis and Retreatment\/Crossover Substudy Results of VenR for Patients with Relapsed\/Refractory CLL. Blood. 2025 Feb 26.","DOI":"10.1182\/blood.2024025525"},{"key":"18059694.2026.1_14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"Hallek","year":"2025","journal-title":"Am J Hematol."},{"key":"18059694.2026.1_15","doi-asserted-by":"crossref","unstructured":"\u0160pa\u010dek M, \u0160imkovi\u010d M, Posp\u00ed\u0161ilov\u00e1 \u0160, et al. Recommendations for Chronic Lymphocytic Leukaemia Diagnosis and Therapy. Transfuze Hematol Dnes. 2025; 31(3).","DOI":"10.48095\/cctahd2025prolekare.cz15"},{"key":"18059694.2026.1_16","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med."},{"key":"18059694.2026.1_17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood."},{"key":"18059694.2026.1_18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"Puente","year":"2011","journal-title":"Nature."},{"key":"18059694.2026.1_19","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med."},{"key":"18059694.2026.1_20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","volume":"121","author":"Oscier","year":"2013","journal-title":"Blood."},{"key":"18059694.2026.1_21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia."},{"key":"18059694.2026.1_22","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood."},{"key":"18059694.2026.1_23","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood."},{"key":"18059694.2026.1_24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"Landau","year":"2013","journal-title":"Cell."},{"key":"18059694.2026.1_25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/leu.2017.291","volume":"32","author":"Nadeu","year":"2018","journal-title":"Leukemia."},{"key":"18059694.2026.1_26","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2023022564","volume":"143","author":"Langerbeins","year":"2024","journal-title":"Blood."},{"key":"18059694.2026.1_27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood."},{"key":"18059694.2026.1_28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"18059694.2026.1_29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2024013474","volume":"9","author":"Shanafelt","year":"2025","journal-title":"Blood Adv."},{"key":"18059694.2026.1_30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood."},{"key":"18059694.2026.1_31","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica."},{"key":"18059694.2026.1_32","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia."},{"key":"18059694.2026.1_33","first-page":"1021","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"18059694.2026.1_34","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet."},{"key":"18059694.2026.1_35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol."},{"key":"18059694.2026.1_36","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol."},{"key":"18059694.2026.1_37","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"key":"18059694.2026.1_38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med."},{"key":"18059694.2026.1_39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol."},{"key":"18059694.2026.1_40","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood."},{"key":"18059694.2026.1_41","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1038\/s41375-025-02611-9","volume":"39","author":"Mashima","year":"2025","journal-title":"Leukemia."},{"key":"18059694.2026.1_42","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/bloodadvances.2024014206","volume":"9","author":"Brown","year":"2025","journal-title":"Blood Adv."},{"key":"18059694.2026.1_43","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"Brown","year":"2024","journal-title":"Blood."},{"key":"18059694.2026.1_44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med."},{"key":"18059694.2026.1_45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"key":"18059694.2026.1_46","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/bloodadvances.2023011327","volume":"8","author":"Lew","year":"2024","journal-title":"Blood Adv."},{"key":"18059694.2026.1_47","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res."},{"key":"18059694.2026.1_48","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/bloodadvances.2025016006","volume":"9","author":"Yoon","year":"2025","journal-title":"Blood Adv."},{"key":"18059694.2026.1_49","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood-2023-179529","volume":"142","author":"Siddiqi","year":"2023","journal-title":"Blood"},{"key":"18059694.2026.1_50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"key":"18059694.2026.1_51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"18059694.2026.1_52","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.3324\/haematol.2018.197889","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"key":"18059694.2026.1_53","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3109\/10428194.2016.1142082","volume":"57","author":"Andersen","year":"2016","journal-title":"Leuk Lymphoma."},{"key":"18059694.2026.1_54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","volume":"33","author":"Wadhwa","year":"2006","journal-title":"Semin Oncol."},{"key":"18059694.2026.1_55","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/bloodadvances.2018026591","volume":"3","author":"Ishdorj","year":"2019","journal-title":"Blood Adv."},{"key":"18059694.2026.1_56","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"Riches","year":"2013","journal-title":"Blood."},{"key":"18059694.2026.1_57","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res."},{"key":"18059694.2026.1_58","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1158\/1078-0432.CCR-11-2630","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res."},{"key":"18059694.2026.1_59","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia."},{"key":"18059694.2026.1_60","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","volume":"99","author":"Tsukada","year":"2002","journal-title":"Blood."},{"key":"18059694.2026.1_61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia."},{"key":"18059694.2026.1_62","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","volume":"126","author":"Sun","year":"2015","journal-title":"Blood."},{"key":"18059694.2026.1_63","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest."},{"key":"18059694.2026.1_64","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","volume":"114","author":"Burger","year":"2009","journal-title":"Blood."},{"key":"18059694.2026.1_65","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/blood-2018-99-117618","volume":"132","author":"Sharpe","year":"2018","journal-title":"Blood"},{"key":"18059694.2026.1_66","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv."},{"key":"18059694.2026.1_67","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1182\/blood-2022-158275","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"18059694.2026.1_68","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1182\/bloodadvances.2023010236","volume":"7","author":"Moreno","year":"2023","journal-title":"Blood Adv."},{"key":"18059694.2026.1_69","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.22094","volume":"107","author":"Francis","year":"2006","journal-title":"Cancer."},{"key":"18059694.2026.1_70","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41375-020-0980-0","volume":"35","author":"Andersen","year":"2021","journal-title":"Leukemia."},{"key":"18059694.2026.1_71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis."},{"key":"18059694.2026.1_72","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"18059694.2026.1_73","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood."},{"key":"18059694.2026.1_74","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia."},{"key":"18059694.2026.1_75","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00277-023-05147-z","volume":"102","author":"\u0160imkovi\u010d","year":"2023","journal-title":"Ann Hematol."},{"key":"18059694.2026.1_76","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ajh.27218","volume":"99","author":"Campanella","year":"2024","journal-title":"Am J Hematol."},{"key":"18059694.2026.1_77","doi-asserted-by":"crossref","first-page":"102307","DOI":"10.1016\/j.eclinm.2023.102307","volume":"65","author":"Chatzikonstantinou","year":"2023","journal-title":"eClinicalMedicine."},{"key":"18059694.2026.1_78","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"J Clin Oncol."},{"key":"18059694.2026.1_79","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol."},{"key":"18059694.2026.1_80","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"18059694.2026.1_81","unstructured":"Munir T, Girvan S, Cairns DA, et al. Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2025 Jun 15."},{"key":"18059694.2026.1_82","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2217\/fon-2022-0456","volume":"18","author":"Ryan","year":"2022","journal-title":"Future Oncol."},{"key":"18059694.2026.1_83","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.2023022993","volume":"143","author":"Casan","year":"2024","journal-title":"Blood."},{"key":"18059694.2026.1_84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-024-01533-w","volume":"17","author":"Zhong","year":"2024","journal-title":"J Hematol Oncol."},{"key":"18059694.2026.1_85","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","volume":"144","author":"Liu","year":"2024","journal-title":"Blood."},{"key":"18059694.2026.1_86","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2023-183071","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"18059694.2026.1_87","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet."}],"container-title":["Acta Medica (Hradec Kralove, Czech Republic)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/actamedica.lfhk.cuni.cz\/media\/pdf\/am_2025068040113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/actamedica.lfhk.cuni.cz\/media\/pdf\/am_2025068040113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:34:50Z","timestamp":1779960890000},"score":1,"resource":{"primary":{"URL":"https:\/\/actamedica.lfhk.cuni.cz\/68\/4\/0113\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025]]}},"alternative-id":["am_2025068040113"],"URL":"https:\/\/doi.org\/10.14712\/18059694.2026.1","relation":{},"ISSN":["1211-4286","1805-9694"],"issn-type":[{"value":"1211-4286","type":"print"},{"value":"1805-9694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}